Metraipolis › archive › dc_fca554a7d3bc

Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies — Europe PMC PMID:41463055

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41463055
DOI: 10.3390/biomedicines13123044
License (as archived): solo-consultazione
Archived: 2026-11-07T17:32:20.088Z
SHA-256 of the archived text: eb995053dfd93074e0259f28f2de9590fe0150936cb1386d3e11c342210ebc57
Stable URL of this page: https://metraipolis.com/documento/dc_fca554a7d3bc

How to cite

Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies — Europe PMC PMID:41463055 — Europe PMC (en), https://europepmc.org/article/MED/41463055 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fca554a7d3bc (Metraipolis archive dc_fca554a7d3bc, sha256 eb995053dfd93074e0259f28f2de9590fe0150936cb1386d3e11c342210ebc57)

BibTeX

@misc{dcfca554a7d3bc,
  title = {Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies — Europe PMC PMID:41463055},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41463055},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fca554a7d3bc; sha256 eb995053dfd93074e0259f28f2de9590fe0150936cb1386d3e11c342210ebc57},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41463055. Agents can read the archived copy with the MCP tool read_document.